Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison Between Palpatory and Ultrasound-guided Methods for Botulinum Toxin Administration in Spastic Paraplegia
NCT07803276Phase 4Recruiting
- Sponsor
- Universidade Federal Fluminense
- Start
- Apr 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 4, double-blind, single-arm trial of botulinum toxin type A in hereditary spastic paraplegia (HSP), sponsored by Universidade Federal Fluminense. Primary endpoints: Modified Ashworth Scale at 20 weeks, Goal Attainment Scaling at 20 weeks and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
hereditary spastic paraplegia (HSP)
Beyond the preview
Go deeper on NCT07803276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803276.